About US

HDT Bio is a Seattle-based clinical stage biopharmaceutical development company developing advanced RNA vaccine products to harness immune system’s response against a variety of disease conditions. HDT Bio’s innovative vaccine platform aims to stabilize and deliver RNA to the immune system to prevent or treat infectious diseases and cancer. Its AMPLIFY vaccine platform is the first self-replicating RNA (repRNA) to receive regulatory authorization anywhere in the world.​

Multidisciplinary Team

HDT Bio’s multidisciplinary team brings extensive regulatory, business, scientific and clinical development experience needed to navigate the intricate process of bringing new products to market, from ideation to regulatory approval, enabling us to deliver unique solutions that transform healthcare.

 

Driving Clinical Development Excellence

HDT Bio’s commitment to excellence in clinical development is evident in its track record of establishing connections with leading academic medical centers, government organizations and foundations both domestically and internationally towards achieving clinical development success. By capitalizing on its previous experience, HDT Bio streamlines the development process, expedites clinical trials, and brings life-saving vaccines to patients in need.

 

Embracing Diversity and Inclusion

By fostering a diverse workforce, HDT Bio taps into a range of perspectives, experiences, and talents, promoting innovation and ensuring that its solutions meet the unique needs of diverse patient populations.

HDT-1045
HDT-5974
HDT-1537
HDT-1462
HDT-1475
HDT-1374
HDT-1366
HDT-1457
HDT-1332
HDT-1284
HDT-1410
HDT-1262
HDT-1175
HDT-1154
HDT-1130
Slide
HDT-1083
HDT-5995
Slide
Slide
Slide
previous arrow
next arrow

Global Value Creation

By providing safe, effective, and innovative products that improve lives around the world, HDT Bio is poised for significant growth through global clinical trials, government grants, and strategic partnerships. Making HDT Bio’s products widely available allows the company to make a meaningful difference on a global scale and realize success in multiple markets.

Achieving Global Health Equity

HDT Bio is dedicated to combining for-profit goals with global health equity objectives. The company’s strategy emphasizes an integrative approach, generating platform and product validation through international partnerships that accelerate pathways to patient access globally. By leveraging both RNA platforms in infectious diseases and exploration of new therapeutic areas, HDT Bio delivers life-changing solutions that have a positive impact on patients, healthcare providers, and society.

Evidence-Based Excellence

By prioritizing rigorous clinical research, generating robust data, and conducting focused clinical trials, HDT Bio strengthens the foundation of its RNA platforms and validates its capabilities in developing novel approaches to prevent and treat disease.